News
IKT
1.800
-0.55%
-0.010
Inhibikase grants 685,718 inducement stock options to five new hires at $1.68/share
Reuters · 1d ago
INHIBIKASE THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT), Tvardi Therapeutics (TVRD) and Apogee Therapeutics (APGE)
TipRanks · 2d ago
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright
TipRanks · 5d ago
Weekly Report: what happened at IKT last week (0323-0327)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Rockwell Med (RMTI) and Inhibikase Therapeutics (IKT)
TipRanks · 03/27 13:10
Inhibikase Therapeutics GAAP EPS of -$0.49
Seeking Alpha · 03/26 20:36
Inhibikase Therapeutics FY2025 net loss widens 75.39% to $48 million; R&D expenses climb 73.13% to $30 million
Reuters · 03/26 20:05
Inhibikase Therapeutics Q1 EPS $(0.10) Beats $(0.13) Estimate
Benzinga · 03/26 20:04
Press Release: Inhibikase Therapeutics Announces -2-
Dow Jones · 03/26 20:01
Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Dow Jones · 03/26 20:01
Weekly Report: what happened at IKT last week (0316-0320)?
Weekly Report · 03/23 09:11
Weekly Report: what happened at IKT last week (0309-0313)?
Weekly Report · 03/16 09:11
Weekly Report: what happened at IKT last week (0302-0306)?
Weekly Report · 03/09 09:11
Inhibikase Therapeutics Price Target Announced at $4.00/Share by Ladenburg Thalmann
Dow Jones · 03/04 13:03
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4
Benzinga · 03/04 12:53
Inhibikase Therapeutics initiated with a Buy at Ladenburg
TipRanks · 03/04 11:48
Weekly Report: what happened at IKT last week (0223-0227)?
Weekly Report · 03/02 09:11
Buy Rating on Inhibikase Therapeutics Driven by Rival PAH Setback and Pivotal Phase 3 IMPROVE-PAH Trial for IKT-001
TipRanks · 02/24 11:16
Analysts Are Bullish on These Healthcare Stocks: Inhibikase Therapeutics (IKT), MoonLake Immunotherapeutics (MLTX)
TipRanks · 02/23 20:10
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).